{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:49:56Z","timestamp":1791272996221,"version":"4.1.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.clbc.2023.08.003","type":"journal-article","created":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T21:30:06Z","timestamp":1692653406000},"page":"835-846","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Safety and Serum Estradiol Levels in Hormonal Treatments for Vulvovaginal Atrophy in Breast Cancer Survivors: A Systematic Review and Meta-Analysis"],"prefix":"10.1016","volume":"23","author":[{"given":"Ana Carolina M.","family":"Comini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno M.","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matheus Jos\u00e9 Barbosa","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8710-1784","authenticated-orcid":false,"given":"Pedro C. Abrah\u00e3o","family":"Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Colapietro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Northern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Batalini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clbc.2023.08.003_bib0001","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/ijc.29364","article-title":"The effects of population-based mammography screening starting between age 40 and 50 in the presence of adjuvant systemic therapy","volume":"137","author":"de Gelder","year":"2015","journal-title":"Int J Cancer"},{"issue":"11","key":"10.1016\/j.clbc.2023.08.003_bib0002","doi-asserted-by":"crossref","first-page":"dju289","DOI":"10.1093\/jnci\/dju289","article-title":"Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality","volume":"106","author":"Munoz","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.clbc.2023.08.003_bib0003","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","article-title":"Breast cancer","volume":"5","author":"Harbeck","year":"2019","journal-title":"Nature Rev Dis Primers"},{"issue":"3","key":"10.1016\/j.clbc.2023.08.003_bib0004","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1604700","article-title":"Extending aromatase-inhibitor adjuvant therapy to 10 years","volume":"375","author":"Goss","year":"2016","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.clbc.2023.08.003_bib0005","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1200\/JCO.2004.08.029","article-title":"Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial","volume":"22","author":"Fallowfield","year":"2004","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2023.08.003_bib0006","doi-asserted-by":"crossref","first-page":"26.e1","DOI":"10.1016\/j.ajog.2010.08.035","article-title":"Urogenital disorders in women with adjuvant endocrine therapy after early breast cancer","volume":"204","author":"Baumgart","year":"2011","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"10.1016\/j.clbc.2023.08.003_bib0007","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/annonc\/mdj127","article-title":"Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors","volume":"17","author":"Kendall","year":"2006","journal-title":"Ann Oncol"},{"issue":"10001","key":"10.1016\/j.clbc.2023.08.003_bib0008","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(15)61074-1","article-title":"Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials","volume":"386","year":"2015","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.clbc.2023.08.003_bib0009","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S1470-2045(21)00758-0","article-title":"Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials","volume":"23","year":"2022","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.clbc.2023.08.003_bib0010","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/GME.0000000000000329","article-title":"Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society","volume":"21","author":"Portman","year":"2014","journal-title":"Menopause"},{"issue":"1","key":"10.1016\/j.clbc.2023.08.003_bib0011","first-page":"43","article-title":"American Cancer Society\/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline","volume":"66","author":"Runowicz","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"10.1016\/j.clbc.2023.08.003_bib0012","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1097\/GME.0b013e3182a122c2","article-title":"Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society","volume":"20","year":"2013","journal-title":"Menopause"},{"issue":"8","key":"10.1016\/j.clbc.2023.08.003_bib0013","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.clbc.2017.05.008","article-title":"Vaginal atrophy in breast cancer survivors: attitude and approaches among oncologists","volume":"17","author":"Biglia","year":"2017","journal-title":"Clin Breast Cancer"},{"issue":"9","key":"10.1016\/j.clbc.2023.08.003_bib0014","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1097\/GME.0000000000001609","article-title":"The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society","volume":"27","year":"2020","journal-title":"Menopause"},{"key":"10.1016\/j.clbc.2023.08.003_bib0015","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.clbc.2023.08.003_bib0016","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.clbc.2023.08.003_bib0017","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.clbc.2023.08.003_bib0018","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1200\/JOP.2011.000352","article-title":"Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator","volume":"8","author":"Wills","year":"2012","journal-title":"J Oncol Pract"},{"issue":"1","key":"10.1016\/j.clbc.2023.08.003_bib0019","first-page":"187","article-title":"Changes in serum estradiol levels with Estring in postmenopausal women with breast cancer treated with aromatase inhibitors","volume":"29","author":"Streff","year":"2021","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clbc.2023.08.003_sbref0020","series-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]","year":"2011"},{"issue":"1","key":"10.1016\/j.clbc.2023.08.003_bib0021","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/jrsm.1230","article-title":"Basics of meta-analysis: I2 is not an absolute measure of heterogeneity","volume":"8","author":"Borenstein","year":"2017","journal-title":"Res Synth Methods"},{"issue":"9","key":"10.1016\/j.clbc.2023.08.003_bib0022","doi-asserted-by":"crossref","first-page":"723","DOI":"10.2165\/11535670-000000000-00000","article-title":"Frequency of treatment-effect modification affecting indirect comparisons: a systematic review","volume":"28","author":"Coory","year":"2010","journal-title":"Pharmacoeconomics"},{"issue":"7","key":"10.1016\/j.clbc.2023.08.003_bib0023","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-010247","article-title":"Plea for routinely presenting prediction intervals in meta-analysis","volume":"6","author":"IntHout","year":"2016","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.clbc.2023.08.003_bib0024","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/cmt.6.1.45.52","article-title":"A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer","volume":"6","author":"Dew","year":"2003","journal-title":"Climacteric"},{"issue":"6","key":"10.1016\/j.clbc.2023.08.003_bib0026","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3109\/09513591003632258","article-title":"Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study","volume":"26","author":"Biglia","year":"2010","journal-title":"Gynecol Endocrinol"},{"issue":"3","key":"10.1016\/j.clbc.2023.08.003_bib0027","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3109\/13697137.2010.529967","article-title":"Vaginal estriol to overcome side-effects of aromatase inhibitors in breast cancer patients","volume":"14","author":"Pfeiler","year":"2011","journal-title":"Climacteric"},{"issue":"2","key":"10.1016\/j.clbc.2023.08.003_bib0025","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10549-012-2198-y","article-title":"Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study","volume":"135","author":"Le Ray","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.clbc.2023.08.003_bib0030","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s10549-014-2930-x","article-title":"Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor(\u00ae)) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study","volume":"145","author":"Donders","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2023.08.003_bib0028","volume":"57","author":"Sanchez Rovira","year":"2016","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.clbc.2023.08.003_bib0034","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1634\/theoncologist.2010-0435","article-title":"Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I\/II study","volume":"16","author":"Witherby","year":"2011","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.clbc.2023.08.003_bib0033","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/sm2.22","article-title":"Breast cancer, aromatase inhibitor therapy, and sexual functioning: a pilot study of the effects of vaginal testosterone therapy","volume":"2","author":"Dahir","year":"2014","journal-title":"Sex Med"},{"issue":"3","key":"10.1016\/j.clbc.2023.08.003_bib0031","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1001\/jamaoncol.2016.3904","article-title":"Vaginal testosterone cream vs estradiol vaginal ring for vaginal dryness or decreased libido in women receiving aromatase inhibitors for early-stage breast cancer: a randomized clinical trial","volume":"3","author":"Melisko","year":"2017","journal-title":"JAMA Oncol"},{"issue":"11","key":"10.1016\/j.clbc.2023.08.003_bib0032","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.1210\/jc.2018-01345","article-title":"Intravaginal testosterone improves sexual satisfaction and vaginal symptoms associated with aromatase inhibitors","volume":"103","author":"Davis","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clbc.2023.08.003_bib0039","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.maturitas.2020.06.021","article-title":"No increase in incidence or risk of recurrence of breast cancer in ospemifene-treated patients with vulvovaginal atrophy (VVA)","volume":"142","author":"Cai","year":"2020","journal-title":"Maturitas"},{"issue":"7","key":"10.1016\/j.clbc.2023.08.003_bib0040","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1080\/09513590.2022.2083103","article-title":"Long-term use of ospemifene in clinical practice for vulvo-vaginal atrophy: end results at 12 months of follow-up","volume":"38","author":"Pingarr\u00f3n Santof\u00edmia","year":"2022","journal-title":"Gynecol Endocrinol"},{"issue":"2","key":"10.1016\/j.clbc.2023.08.003_bib0036","first-page":"643","article-title":"Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance)","volume":"26","author":"Barton","year":"2018","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clbc.2023.08.003_bib0035","first-page":"1","article-title":"Safety of prasterone in breast cancer survivors treated with aromatase inhibitors: the VIBRA pilot study","author":"Mension","year":"2022","journal-title":"Climacteric"},{"issue":"7","key":"10.1016\/j.clbc.2023.08.003_bib0041","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1093\/jnci\/djn058","article-title":"Increased risk of recurrence after hormone replacement therapy in breast cancer survivors","volume":"100","author":"Holmberg","year":"2008","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.clbc.2023.08.003_bib0042","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejca.2012.07.003","article-title":"Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial","volume":"49","author":"Fahl\u00e9n","year":"2013","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.clbc.2023.08.003_bib0043","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/jnci\/93.10.754","article-title":"Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality","volume":"93","author":"O'Meara","year":"2001","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"10.1016\/j.clbc.2023.08.003_bib0044","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1093\/jnci\/djac112","article-title":"Systemic or vaginal hormone therapy after early breast cancer: a Danish Observational Cohort Study","volume":"114","author":"Cold","year":"2022","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"10.1016\/j.clbc.2023.08.003_bib0045","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1001\/jama.1994.03520070060039","article-title":"Estrogen replacement therapy in breast cancer survivors. A time for change. Breast Cancer Committees of the Eastern Cooperative Oncology Group","volume":"272","author":"Cobleigh","year":"1994","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.clbc.2023.08.003_bib0046","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1006\/gyno.1997.4621","article-title":"Estrogen replacement therapy in women with prior diagnosis and treatment for breast cancer","volume":"65","author":"Vassilopoulou-Sellin","year":"1997","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.clbc.2023.08.003_bib0047","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1200\/JCO.1999.17.5.1482","article-title":"Estrogen replacement therapy after localized breast cancer: clinical outcome of 319 women followed prospectively","volume":"17","author":"Vassilopoulou-Sellin","year":"1999","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clbc.2023.08.003_bib0048","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/S0002-9378(96)70594-X","article-title":"Hormone replacement therapy in breast cancer survivors: a cohort study","volume":"174","author":"DiSaia","year":"1996","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.clbc.2023.08.003_bib0049","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S0002-9378(99)70550-8","article-title":"Estrogen replacement therapy in women with previous breast cancer","volume":"181","author":"Natrajan","year":"1999","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.clbc.2023.08.003_bib0050","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1159\/000055319","article-title":"Hormone replacement therapy after treatment of breast cancer: effects on postmenopausal symptoms, bone mineral density and recurrence rates","volume":"60","author":"Beckmann","year":"2001","journal-title":"Oncology"},{"issue":"8","key":"10.1016\/j.clbc.2023.08.003_bib0051","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1200\/JCO.2001.19.8.2357","article-title":"Hormone replacement therapy after breast cancer: a systematic review and quantitative assessment of risk","volume":"19","author":"Col","year":"2001","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.clbc.2023.08.003_bib0052","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1097\/GME.0000000000000131","article-title":"Hypoactive sexual desire in women","volume":"20","author":"Kingsberg","year":"2013","journal-title":"Menopause"},{"key":"10.1016\/j.clbc.2023.08.003_bib0053","first-page":"105","article-title":"Treating dyspareunia caused by vaginal atrophy: a review of treatment options using vaginal estrogen therapy","volume":"1","author":"Kingsberg","year":"2010","journal-title":"Int J Womens Health"},{"issue":"14","key":"10.1016\/j.clbc.2023.08.003_bib0055","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1200\/JCO.2013.53.9411","article-title":"Interpreting plasma estrogen levels in breast cancer: caution needed","volume":"32","author":"Folkerd","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1-2","key":"10.1016\/j.clbc.2023.08.003_bib0056","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jsbmb.2007.09.023","article-title":"Effects of intravaginal dehydroepiandrosterone on vaginal histomorphology, sex steroid receptor expression and cell proliferation in the rat","volume":"109","author":"Berger","year":"2008","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"12","key":"10.1016\/j.clbc.2023.08.003_bib0057","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1158\/1078-0432.CCR-19-3091","article-title":"Anastrozole has an association between degree of estrogen suppression and outcomes in early breast cancer and is a ligand for estrogen receptor \u03b1","volume":"26","author":"Ingle","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.clbc.2023.08.003_bib0058","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/j.fertnstert.2003.12.016","article-title":"First uterine pass effect\u201d is observed when estradiol is placed in the upper but not lower third of the vagina","volume":"81","author":"Cicinelli","year":"2004","journal-title":"Fertil Steril"},{"key":"10.1016\/j.clbc.2023.08.003_bib0059","first-page":"19","article-title":"Optimal use of SERMS after menopause","volume":"19","author":"Pickar","year":"2016","journal-title":"Climacteric"},{"issue":"3","key":"10.1016\/j.clbc.2023.08.003_bib0060","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3109\/13697137.2010.483297","article-title":"Minimized estradiol absorption with ultra-low-dose 10 microg 17beta-estradiol vaginal tablets","volume":"13","author":"Eugster-Hausmann","year":"2010","journal-title":"Climacteric"},{"issue":"2","key":"10.1016\/j.clbc.2023.08.003_bib0061","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3109\/13697137.2014.954996","article-title":"Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial","volume":"18","author":"Constantine","year":"2015","journal-title":"Climacteric"},{"key":"10.1016\/j.clbc.2023.08.003_bib0062","first-page":"605","article-title":"Ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy: potential benefits in bone and breast","volume":"5","author":"Soe","year":"2013","journal-title":"Int J Womens Health"},{"issue":"7","key":"10.1016\/j.clbc.2023.08.003_bib0063","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1097\/GME.0000000000000624","article-title":"Effects of ospemifene, a novel selective estrogen-receptor modulator, on human breast tissue ex vivo","volume":"23","author":"Eigeliene","year":"2016","journal-title":"Menopause"},{"key":"10.1016\/j.clbc.2023.08.003_bib0064","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2147\/IJWH.S36026","article-title":"Overcoming resistance and barriers to the use of local estrogen therapy for the treatment of vaginal atrophy","volume":"4","author":"Chism","year":"2012","journal-title":"Int J Womens Health"},{"key":"10.1016\/j.clbc.2023.08.003_bib0065","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1634\/theoncologist.2007-0234","article-title":"Should urogenital atrophy in breast cancer survivors be treated with topical estrogens?","volume":"13","author":"Trinkaus","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.clbc.2023.08.003_bib0066","first-page":"597","article-title":"Cigarette smoking and vaginal atrophy in postmenopausal women","volume":"10","author":"Kalogeraki","year":"1996","journal-title":"In Vivo"},{"key":"10.1016\/j.clbc.2023.08.003_bib0067","first-page":"1826","article-title":"Weight reduction as treatment of urinary incontinence","volume":"106","author":"Altman","year":"2009","journal-title":"Lakartidningen"},{"key":"10.1016\/j.clbc.2023.08.003_bib0068","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/gme.0b013e318051718c","article-title":"The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society","volume":"14","year":"2007","journal-title":"Menopause"},{"key":"10.1016\/j.clbc.2023.08.003_bib0069","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejogrb.2022.08.012","article-title":"Fractional Co2 laser for vulvo-vaginal atrophy in gynecologic cancer patients: a valid therapeutic choice? A systematic review","volume":"277","author":"D'Oria","year":"2022","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.clbc.2023.08.003_bib0070","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.maturitas.2020.02.009","article-title":"Safety evaluation of fractional CO2 laser treatment in post-menopausal women with vaginal atrophy: a prospective observational study","volume":"135","author":"Di Donato","year":"2020","journal-title":"Maturitas"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820923002100?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820923002100?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:24:49Z","timestamp":1761513889000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820923002100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":66,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S1526820923002100"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2023.08.003","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and Serum Estradiol Levels in Hormonal Treatments for Vulvovaginal Atrophy in Breast Cancer Survivors: A Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2023.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}